 ATLANTA--BUSINESS WIRE--- VIRI Antiviral--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced today that the United States Patent and Trademark Office USPTO has granted Virios Therapeutics patent exclusivity on its valacyclovir-celecoxib combination drug candidate to 2033. The Companys intellectual property portfolio now includes 21 issued patents, consisting of 13 iss 